Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Vaccination site pain
Clinical narrative: Chills; Injection site pain; Fatigue; Headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 16 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 12Apr2021 01:15 (Lot number: EP6955) at the age of 16 years as dose 2,single for covid-19 immunisation. Relevant medical history included: "Attention deficit hyperactivity disorder" (unspecified if ongoing). Concomitant medication(s) included: FOCALIN [DEXMETHYLPHENIDATE HYDROCHLORIDE]. Vaccination history included: Bnt162b2 (Suspected drug: Pfizer covid vaccine, Dose number-1,, Lot number= EN62041, lot unknown=False,, Administration time=11:15 AM, Vaccine location=Right arm), administration date: 22Mar2021, for Covid-19 immunization. The following information was reported: CHILLS (non-serious) with onset 12Apr2021 23:30, outcome "recovered" (Apr2021), described as "Chills"; VACCINATION SITE PAIN (non-serious) with onset 12Apr2021 23:30, outcome "recovered" (16Apr2021), described as "Injection site pain"; FATIGUE (non-serious) with onset 12Apr2021 23:30, outcome "recovered" (16Apr2021), described as "Fatigue"; HEADACHE (non-serious) with onset 12Apr2021 23:30, outcome "recovered" (16Apr2021), described as "Headache". Therapeutic measures were taken as a result of chills, vaccination site pain, fatigue, headache.  Additional Information: It was reported that no other vaccine received in four weeks.Treatment medication included Ibuprofen, acetaminophen. It was reported that patient was not Covid tested prior and post vaccination. No known allergies. Vaccine Facility information available.Ethnicity information is available. Race information is available.It was reported that The Pfizer Drug safety unit recently received the report submitted by reporter via Pfizer safety reporting.com. They asked to confirm the date that reporter became aware of the adverse events in this report as this effects regulatory reporting timelines. This awareness date is the date reporter became aware of the occurrence of the reported events. If reporter is the patient in the case, the awareness date would be the date that she became aware in experiencing the reported events. If she is not the patient in the case, the awareness date would be the date she became aware of the occurrence of the reported events.This awareness date represents the Pfizer receipt date of the report and reflects the earliest date that any Pfizer colleague learned of the adverse event. If she learned of these events from another Pfizer colleague, they asked to provide the date that the first Pfizer colleague became aware of the events reported, as regulatory reporting due dates are calculated based on the first day that a Pfizer colleague became aware of the adverse events.Reporter replied she was aware of these AEs when they started on 12APR2021, and reported when they resolved to completion on 16APR2021. Pfizer US Drug safety unit asked to provide delay comment for the same.  No follow-up attempts are possible. No further information is expected.